GTx says prostate-cancer drug reduces hot flashes in men
March 3 (Reuters) - Biotechnology company GTx Inc (GTXI.O: Quote, Profile, Research, Stock Buzz) said a late-stage trial showed its experimental drug, toremifene citrate, reduced hot flashes in men who were on Androgen deprivation therapy, a common treatment for advanced prostate cancer.
In late February, the company said a late-stage trial showed the drug reduced spinal fractures and other side effects caused by Androgen deprivation therapy. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Pratish Narayanan)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Obama's economic stimulus plan